{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:14:30Z","timestamp":1770009270094,"version":"3.49.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>In a minority of differentiated thyroid cancer (TC) cases and in a large percentage of poorly differentiated TCs (PDTCs) and anaplastic TCs (ATCs), the prognosis is poor due to the lack of response to conventional treatments. In the last two decades, multikinase inhibitor (MKI) compounds have been developed and demonstrated to be very effective in these aggressive cases. Besides the great efficacy, several adverse events (AEs) have been reported in virtually all patients treated with MKIs, largely overlapping between different compounds and including hypertension, diarrhea, anorexia, decreased weight, fatigue, and proteinuria. Most grade 3\u20134 adverse reactions occur during the first 6 months of treatment and require dosage reduction and\/or drug discontinuation. Due to severity of the AEs related to the treatment with MKIs, a multidisciplinary team is definitely required for the daily management of these patients, for the evaluation of the disease status, and the psychophysical condition. Moreover, it is crucial that the patients could have a facilitated access to reach either specialist doctors or nurses who must have been trained to follow them for their individual clinical complications. The follow-up visits should take place at monthly intervals until the sixth month and then every 1\u20132 months until the completion of the first year of treatment. The flow chart followed at our tertiary center is reported in the present review as a real-life-based example for the follow-up of patients with advanced TC on MKI treatment.<\/jats:p>","DOI":"10.3389\/fonc.2022.903532","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T18:35:23Z","timestamp":1656959723000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Daily Management of Patients on Multikinase Inhibitors\u2019 Treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Carla","family":"Colombo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Giancola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Scaltrito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fugazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000502229","article-title":"European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib Versus Placebo in Radioiodine-Refractory Thyroid Cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","article-title":"Real-World Efficacy and Safety of Lenvatinib: Data From a Compassionate Use in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer Patients in Italy","volume":"118","author":"Locati","year":"2019","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0205","article-title":"Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice","volume":"28","author":"Berdelou","year":"2018","journal-title":"Thyroid"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0221","article-title":"Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences","volume":"30","author":"Masaki","year":"2020","journal-title":"Thyroid"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0763","article-title":"Effectiveness and Toxicity of Lenvatinib in Refractory Thyroid Cancer: Dutch Real-Life Data","volume":"182","author":"Aydemirli","year":"2020","journal-title":"Eur J Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02290-9","article-title":"Real-Life Use of Lenvatinib in Patients With Differentiated Thyroid Cancer: Experience From Argentina","volume":"69","author":"Jerkovich","year":"2020","journal-title":"Endocrine"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0476","article-title":"Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated With Survival: A Multicenter Study in Korea","volume":"30","author":"Song","year":"2020","journal-title":"Thyroid"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7150\/jca.22318","article-title":"Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program","volume":"9","author":"Balmelli","year":"2018","journal-title":"J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12396","article-title":"Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer: A Snapshot of Real-Life Clinical Practice","volume":"38","author":"Nervo","year":"2018","journal-title":"Anticancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00384","article-title":"Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea","volume":"10","author":"Kim","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0022","article-title":"Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study","volume":"29","author":"Lee","year":"2019","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25784","article-title":"Minami, Exploratory Analysis of Prognostic Factors for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer","volume":"41","author":"Suzuki","year":"2019","journal-title":"Head Neck"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000501691","article-title":"Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience With the Multidisciplinary Approach and Review of Literature","volume":"97","author":"Denaro","year":"2019","journal-title":"Oncology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1507\/endocrj.EJ17-0365","article-title":"Clinical Factors Related to the Efficacy of Tyrosine Kinase Inhibitor Therapy in Radioactive Iodine Refractory Recurrent Differentiated Thyroid Cancer Patients","volume":"65","author":"Sugino","year":"2018","journal-title":"Endocr J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02477-0","article-title":"Lenvatinib as First-Line Treatment for Advanced Thyroid Cancer: Long Progression-Free Survival","volume":"72","author":"De Leo","year":"2021","journal-title":"Endocrine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0361","article-title":"Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results From a French Cohort","volume":"25","author":"Chougnet","year":"2015","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2020.687","article-title":"Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02426-x","article-title":"Long-Term Follow-Up and Safety of Vandetanib for Advanced Medullary Thyroid Cancer","volume":"71","author":"Ramos","year":"2021","journal-title":"Endocrine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2016.1238764","article-title":"The Safety and Efficacy of Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer","volume":"16","author":"Fallahi","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1201060","article-title":"The Safety of Vandetanib for the Treatment of Thyroid Cancer","volume":"15","author":"Tsang","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S127848","article-title":"Evaluating Vandetanib in the Treatment of Medullary Thyroid Cancer: Patient-Reported Outcomes","volume":"11","author":"Fallahi","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in Progressive Medullary Thyroid Cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4158\/EP171822.OR","article-title":"Optimizing Lenvatinib Therapy in Patients With Metastatic Radioactive Iodine-Resistant Differentiated Thyroid Cancers","volume":"23","author":"Jasim","year":"2017","journal-title":"Endocr Pract"},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000508186","article-title":"Quality of Life During Treatment With Lenvatinib for Thyroid Cancer: The Patients' Perspective Beyond the Medical Evaluation","volume":"10","author":"Nervo","year":"2021","journal-title":"Eur Thyroid J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0276","article-title":"Safety and Quality-of-Life Data From an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer","volume":"31","author":"Giani","year":"2021","journal-title":"Thyroid"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.06.019","article-title":"Optimisation of Treatment With Lenvatinib in Radioactive Iodine-Refractory Differentiated Thyroid Cancer","volume":"69","author":"Capdevila","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the Adverse Events Associated With Lenvatinib Therapy in Radioiodine-Refractory Differentiated Thyroid Cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.23736\/S1824-4785.19.03190-X","article-title":"Radioiodine Therapy of Advanced Differentiated Thyroid Cancer: Clinical Considerations and Multidisciplinary Approach","volume":"63","author":"Giovanella","year":"2019","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235961","article-title":"Nursing Management and Adverse Events in Thyroid Cancer Treatments With Tyrosine Kinase Inhibitors","volume":"13","author":"De Leo","year":"2021","journal-title":"A Narrative Review. Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000504048","article-title":"Body Composition and Leptin\/Ghrelin Levels During Lenvatinib for Thyroid Cancer","volume":"9","author":"De Leo","year":"2020","journal-title":"Eur Thyroid J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01836","article-title":"Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy","volume":"104","author":"Colombo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1089\/thy.2021.0040","article-title":"Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated, Common Adverse Event","volume":"32","author":"Monti","year":"2021","journal-title":"Thyroid"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31344","article-title":"Treatment-Emergent Hypertension and Efficacy in the Phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT)","volume":"124","author":"Wirth","year":"2018","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00465-y","article-title":"Multikinase Inhibitors in Thyroid Cancer: Timing of Targeted Therapy","volume":"17","author":"Gild","year":"2021","journal-title":"Nat Rev Endocrinol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.903532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T18:35:24Z","timestamp":1656959724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.903532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":37,"alternative-id":["10.3389\/fonc.2022.903532"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.903532","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"article-number":"903532"}}